AstraZeneca’s Hold Rating Reaffirmed at Deutsche Bank (AZN)
AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by investment analysts at Deutsche Bank in a note issued to investors on Friday, AnalystRatingsNetwork reports. They currently have a GBX 3,600 ($59.09) target price on the stock. Deutsche Bank’s price objective indicates a potential downside of 7.42% from the company’s current price.
AstraZeneca (LON:AZN) traded down 1.81% during mid-day trading on Friday, hitting GBX 3888.4998. The stock had a trading volume of 3,344,786 shares. AstraZeneca has a 52 week low of GBX 2895.00 and a 52 week high of GBX 3963.4998. The stock’s 50-day moving average is GBX 3639. and its 200-day moving average is GBX 3353.59. The company’s market cap is £48.723 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of AstraZeneca in a research note to investors on Tuesday. They now have a GBX 3,112 ($51.08) price target on the stock. Separately, analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca in a research note to investors on Monday. They now have a GBX 3,378.87 ($55.46) price target on the stock. Finally, analysts at Barclays reiterated an “equal weight” rating on shares of AstraZeneca in a research note to investors on Friday, January 17th. They now have a GBX 3,300 ($54.17) price target on the stock. Twelve research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of GBX 3,360.66 ($55.17).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.